thalidomide has been researched along with Waldenstrom Macroglobulinemia in 39 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Waldenstrom Macroglobulinemia: A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide was given orally 21/28 days per cycle for 1 year, at escalated dose of 15 to 20 mg during phase 1 to determine the MTD; the phase 2 part was conducted at the MTD." | 6.80 | Lenalidomide is safe and active in Waldenström macroglobulinemia. ( Arnulf, B; Bakala, J; Banos, A; Bories, C; Brice, P; Choquet, S; Demarquette, H; Dib, M; Fouquet, G; Guidez, S; Herbaux, C; Karlin, L; Leblond, V; LeGouill, S; Leleu, X; Louni, C; Martin, A; Morel, P; Nudel, M; Ohyba, B; Petillon, MO; Poulain, S; Salles, G; Thielemans, B; Tournilhac, O, 2015) |
| " Intended therapy consisted of daily thalidomide (200 mg for 2 weeks, then 400 mg for 50 weeks) and rituximab (375 mg/m(2) per week) dosed on weeks 2 to 5 and 13 to 16." | 6.73 | Thalidomide and rituximab in Waldenstrom macroglobulinemia. ( Anderson, KC; Boedeker, H; Branagan, AR; Briccetti, FM; Chu, L; Chua, C; Ciccarelli, BT; Cooper, RB; Garbo, L; Hatjiharissi, E; Hill, J; Howard, J; Hunter, ZR; Ioakimidis, L; Lovett, DR; Moore, M; Musto, P; Nantel, SH; Pasmantier, M; Patterson, CJ; Rauch, A; Sonneborn, H; Soumerai, JD; Treon, SP; Zimbler, H, 2008) |
| "A POEMS syndrome is a rare disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin abnormalities including hyperpigmentation and hypertrichosis." | 5.36 | Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia. ( Hata, H; Kawano, Y; Kimura, E; Maruyoshi, N; Mitsuya, H; Nakama, T; Uchino, M, 2010) |
| "Lenalidomide produces unexpected but clinically significant acute anemia in patients with WM." | 5.14 | Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. ( Anderson, KC; Baron, AD; Branagan, AR; Chu, L; Hunter, ZR; Hyman, PM; Ioakimidis, L; Kash, JJ; Munshi, NC; Musto, P; Nawfel, EL; Nunnink, JC; Patterson, CJ; Sharon, DJ; Soumerai, JD; Terjanian, TO; Treon, SP, 2009) |
| "Thalidomide acts on the microenvironment of myelodysplastic syndromes (MDS) by influencing cytokine networks, and growing evidence supports thalidomide's usefulness in the management of haematological malignancies, such as MDS." | 3.73 | Future directions in haematology: beyond multiple myeloma. ( Prentice, HG; Russell, N; Sacchi, S, 2005) |
| "Lenalidomide was given orally 21/28 days per cycle for 1 year, at escalated dose of 15 to 20 mg during phase 1 to determine the MTD; the phase 2 part was conducted at the MTD." | 2.80 | Lenalidomide is safe and active in Waldenström macroglobulinemia. ( Arnulf, B; Bakala, J; Banos, A; Bories, C; Brice, P; Choquet, S; Demarquette, H; Dib, M; Fouquet, G; Guidez, S; Herbaux, C; Karlin, L; Leblond, V; LeGouill, S; Leleu, X; Louni, C; Martin, A; Morel, P; Nudel, M; Ohyba, B; Petillon, MO; Poulain, S; Salles, G; Thielemans, B; Tournilhac, O, 2015) |
| " Intended therapy consisted of daily thalidomide (200 mg for 2 weeks, then 400 mg for 50 weeks) and rituximab (375 mg/m(2) per week) dosed on weeks 2 to 5 and 13 to 16." | 2.73 | Thalidomide and rituximab in Waldenstrom macroglobulinemia. ( Anderson, KC; Boedeker, H; Branagan, AR; Briccetti, FM; Chu, L; Chua, C; Ciccarelli, BT; Cooper, RB; Garbo, L; Hatjiharissi, E; Hill, J; Howard, J; Hunter, ZR; Ioakimidis, L; Lovett, DR; Moore, M; Musto, P; Nantel, SH; Pasmantier, M; Patterson, CJ; Rauch, A; Sonneborn, H; Soumerai, JD; Treon, SP; Zimbler, H, 2008) |
| "Twelve patients with Waldenstrom's macroglobulinemia (WM) underwent treatment with the nonmyelosuppressive combination regimen BLT-D: clarithomycin (Biaxin [BXN], Abbott Laboratories, Abbott Park, IL) 500 mg orally twice daily, low-dose thalidomide (THAL) 50 mg orally escalated to 200 mg daily, and dexamethasone (DXM) 40 mg orally once weekly all with modification for toxicity." | 2.71 | Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. ( Coleman, M; Leonard, J; Lyons, L; Niesvizky, R; Szelenyi, H, 2003) |
| "Waldenström macroglobulinemia is defined by the presence of monoclonal immunoglobulin IgM type (M-IgM) and evidence of lymphoplasmacytic bone marrow infiltration." | 2.53 | [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. ( Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S, 2016) |
| "Waldenstrom macroglobulinemia (WM) is a B-cell lymphoplasmacytic lymphoma characterized by monoclonal immunoglobulin M protein in the serum and infiltration of bone marrow with lymphoplasmacytic cells." | 2.52 | Waldenstrom macroglobulinemia: prognosis and management. ( Oza, A; Rajkumar, SV, 2015) |
| "Waldenström's macroglobulinemia is a rare B-cell malignancy defined by medullar infiltration by clonal lymphoplasmocytic cells and monoclonal IgM secretion." | 2.50 | Current and future therapeutic approach for Waldenström's macroglobulinemia. ( Choquet, S; Leblond, V; Nguyen, S; Souchet-Cömpain, L, 2014) |
| "Waldenström macroglobulinemia is a lymphoplasmacytic lymphoma." | 2.49 | Waldenström macroglobulinemia: my way. ( Gertz, M, 2013) |
| "Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder characterized by lymphoplasmacytic bone marrow infiltration along with an immunoglobulin M (IgM) monoclonal gammopathy." | 2.45 | Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. ( Dimopoulos, MA; Fermand, JP; Garcia-Sanz, R; Gertz, MA; Ghobrial, IM; Kastritis, E; Kimby, EK; Kyle, RA; Leblond, V; Merlini, G; Morel, P; Morra, E; Ocio, EM; Owen, R; Seymour, J; Treon, SP, 2009) |
| "Lenalidomide is an immunomodulatory drug, structurally related to thalidomide, with pleiotropic activity including antiangiogenic and antineoplastic properties." | 2.44 | Treatment of plasma cell dyscrasias with lenalidomide. ( Dimopoulos, MA; Kastritis, E; Rajkumar, SV, 2008) |
| "Waldenström macroglobulinemia (WM) is a B-cell malignancy characterized by diffuse bone marrow (BM) infiltration, hepatosplenomegaly, lymphadenopathy, and the presence of a serum IgM monoclonal protein." | 2.44 | Targeted therapies in Waldenström macroglobulinemia. ( Burwick, N; Ghobrial, IM; Leleu, X; Roccaro, AM, 2008) |
| "Lenalidomide is a novel anticancer agent that has made a major impact in the treatment of patients with B-cell malignancies." | 2.44 | Lenalidomide for the treatment of B-cell malignancies. ( Chanan-Khan, AA; Cheson, BD, 2008) |
| "Waldenstrom's macroglobulinemia (WM) remains an incurable B-cell malignancy, necessitating urgent development of novel treatment strategies." | 2.42 | Novel biologically based therapies for Waldenstrom's macroglobulinemia. ( Anderson, KC; Mitsiades, CS; Mitsiades, N; Richardson, PG; Treon, SP, 2003) |
| "Waldenström macroglobulinemia (WM) is rarer than amyloidosis (1500 per year WM versus 3000 per year amyloid in the US), and recent consensus panels have established the definition of the disease, the diagnostic criteria, criteria for initiation of therapy and a new classification scheme." | 2.42 | Amyloidosis and Waldenström's macroglobulinemia. ( Gertz, MA; Merlini, G; Treon, SP, 2004) |
| "Waldenstrom's macroglobulinemia (WM) is a rare chronic B-cell lymphoproliferative disorder characterized by macroglobulin (immunoglobulin M; IgM) paraproteinemia." | 2.42 | Treatment options in Waldenstrom's macroglobulinemia. ( Björkholm, M, 2004) |
| "Immunoglobulin M multiple myeloma and Waldenström macroglobulinemia are two different hematological diseases with the common finding of an immunoglobulin M monoclonal gammopathy of unknown significance." | 1.56 | Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports. ( Bonferroni, M; Castellino, A; Castellino, C; Celeghini, I; Drandi, D; Elba, S; Foglietta, M; Fraternali Orcioni, G; Giordano, F; Grasso, M; Massaia, M; Mattei, D; Mordini, N; Rapezzi, D; Soriasio, R; Strola, G, 2020) |
| "We report on a case of Waldenström's macroglobulinemia (WM) treated with splenic re-irradiation." | 1.38 | Splenic re-irradiation for waldenstrőm's macroglobulinemia. ( Han, W; Wei, Z; Yanxia, Y; Ying, X; Yuhua, J, 2012) |
| "A POEMS syndrome is a rare disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin abnormalities including hyperpigmentation and hypertrichosis." | 1.36 | Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia. ( Hata, H; Kawano, Y; Kimura, E; Maruyoshi, N; Mitsuya, H; Nakama, T; Uchino, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (58.97) | 29.6817 |
| 2010's | 15 (38.46) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Elba, S | 1 |
| Castellino, A | 1 |
| Soriasio, R | 1 |
| Castellino, C | 1 |
| Bonferroni, M | 1 |
| Mattei, D | 1 |
| Strola, G | 1 |
| Drandi, D | 1 |
| Mordini, N | 1 |
| Foglietta, M | 1 |
| Rapezzi, D | 1 |
| Celeghini, I | 1 |
| Grasso, M | 1 |
| Giordano, F | 1 |
| Fraternali Orcioni, G | 1 |
| Massaia, M | 1 |
| Abdallah, AO | 1 |
| Atrash, S | 1 |
| Muzaffar, J | 1 |
| Abdallah, M | 1 |
| Kumar, M | 1 |
| Van Rhee, F | 1 |
| Barlogie, B | 1 |
| Xu, M | 1 |
| Hou, Y | 1 |
| Sheng, L | 1 |
| Peng, J | 1 |
| Paulus, A | 1 |
| Chitta, K | 1 |
| Akhtar, S | 1 |
| Personett, D | 1 |
| Miller, KC | 1 |
| Thompson, KJ | 1 |
| Carr, J | 1 |
| Kumar, S | 1 |
| Roy, V | 1 |
| Ansell, SM | 1 |
| Mikhael, JR | 1 |
| Dispenzieri, A | 1 |
| Reeder, CB | 1 |
| Rivera, CE | 1 |
| Foran, J | 1 |
| Chanan-Khan, A | 1 |
| Souchet-Cömpain, L | 1 |
| Choquet, S | 2 |
| Leblond, V | 3 |
| Nguyen, S | 1 |
| Oza, A | 1 |
| Rajkumar, SV | 3 |
| Cohen, C | 1 |
| Royer, B | 1 |
| Javaugue, V | 1 |
| Szalat, R | 1 |
| El Karoui, K | 1 |
| Caulier, A | 1 |
| Knebelmann, B | 1 |
| Jaccard, A | 1 |
| Chevret, S | 1 |
| Touchard, G | 1 |
| Fermand, JP | 2 |
| Arnulf, B | 2 |
| Bridoux, F | 1 |
| Fouquet, G | 1 |
| Guidez, S | 1 |
| Petillon, MO | 1 |
| Louni, C | 1 |
| Ohyba, B | 1 |
| Dib, M | 1 |
| Poulain, S | 1 |
| Herbaux, C | 1 |
| Martin, A | 1 |
| Thielemans, B | 1 |
| Brice, P | 1 |
| Bakala, J | 1 |
| Bories, C | 1 |
| Demarquette, H | 1 |
| Nudel, M | 1 |
| Tournilhac, O | 1 |
| LeGouill, S | 1 |
| Morel, P | 2 |
| Banos, A | 1 |
| Karlin, L | 1 |
| Salles, G | 1 |
| Leleu, X | 5 |
| Adam, Z | 1 |
| Pour, L | 1 |
| Krejčí, M | 1 |
| Ševčíková, S | 1 |
| Pourová, E | 1 |
| Ševčíková, E | 1 |
| Král, Z | 1 |
| Mayer, J | 1 |
| Ouyang, HY | 1 |
| Yu, ZJ | 1 |
| Yin, J | 1 |
| Zhao, XJ | 1 |
| Wang, ZY | 1 |
| Zhang, W | 1 |
| Ma, ZN | 1 |
| Su, J | 1 |
| Bai, X | 1 |
| Ruan, CG | 1 |
| Dimopoulos, MA | 4 |
| Kastritis, E | 2 |
| Burwick, N | 1 |
| Roccaro, AM | 2 |
| Ghobrial, IM | 3 |
| Moreau, AS | 2 |
| Dupire, S | 1 |
| Robu, D | 1 |
| Gay, J | 1 |
| Hatjiharissi, E | 2 |
| Burwik, N | 1 |
| Treon, SP | 5 |
| Soumerai, JD | 2 |
| Branagan, AR | 2 |
| Hunter, ZR | 2 |
| Patterson, CJ | 2 |
| Ioakimidis, L | 2 |
| Briccetti, FM | 1 |
| Pasmantier, M | 1 |
| Zimbler, H | 1 |
| Cooper, RB | 1 |
| Moore, M | 1 |
| Hill, J | 1 |
| Rauch, A | 1 |
| Garbo, L | 1 |
| Chu, L | 2 |
| Chua, C | 1 |
| Nantel, SH | 1 |
| Lovett, DR | 1 |
| Boedeker, H | 1 |
| Sonneborn, H | 1 |
| Howard, J | 1 |
| Musto, P | 2 |
| Ciccarelli, BT | 1 |
| Anderson, KC | 3 |
| Gertz, MA | 2 |
| Garcia-Sanz, R | 1 |
| Kimby, EK | 1 |
| Merlini, G | 2 |
| Morra, E | 1 |
| Ocio, EM | 1 |
| Owen, R | 1 |
| Seymour, J | 1 |
| Kyle, RA | 2 |
| Baron, AD | 1 |
| Nunnink, JC | 1 |
| Kash, JJ | 1 |
| Terjanian, TO | 1 |
| Hyman, PM | 1 |
| Nawfel, EL | 1 |
| Sharon, DJ | 1 |
| Munshi, NC | 1 |
| Kawano, Y | 1 |
| Nakama, T | 1 |
| Hata, H | 1 |
| Kimura, E | 1 |
| Maruyoshi, N | 1 |
| Uchino, M | 1 |
| Mitsuya, H | 1 |
| Wémeau, M | 1 |
| Gauthier, J | 1 |
| Yakoub-Agha, I | 2 |
| Furuta, N | 1 |
| Tashiro, Y | 1 |
| Ikeda, M | 1 |
| Fujita, Y | 1 |
| Okamoto, K | 1 |
| Wei, Z | 1 |
| Yanxia, Y | 1 |
| Ying, X | 1 |
| Han, W | 1 |
| Yuhua, J | 1 |
| Gertz, M | 1 |
| Rigual, D | 1 |
| Qiu, J | 1 |
| Fenstermaker, RA | 1 |
| Fabiano, AJ | 1 |
| Zinzani, PL | 1 |
| Tani, M | 1 |
| Alinari, L | 1 |
| Stefoni, V | 1 |
| Baccarani, M | 1 |
| Coleman, M | 2 |
| Leonard, J | 2 |
| Lyons, L | 2 |
| Pekle, K | 1 |
| Nahum, K | 1 |
| Pearse, R | 1 |
| Niesvizky, R | 2 |
| Michaeli, J | 1 |
| Tsatalas, C | 1 |
| Zomas, A | 2 |
| Hamilos, G | 1 |
| Panayiotidis, P | 2 |
| Margaritis, D | 1 |
| Matsouka, C | 2 |
| Economopoulos, T | 1 |
| Anagnostopoulos, N | 2 |
| Szelenyi, H | 1 |
| Zeldis, JB | 1 |
| Schafer, PH | 1 |
| Bennett, BL | 1 |
| Mercurio, F | 1 |
| Stirling, DI | 1 |
| Mitsiades, CS | 1 |
| Mitsiades, N | 1 |
| Richardson, PG | 1 |
| Björkholm, M | 1 |
| Micol, JB | 1 |
| Guieze, R | 1 |
| Berthon, C | 1 |
| Kuhnovsky, F | 1 |
| Terriou, L | 1 |
| Bauters, F | 1 |
| Facon, T | 1 |
| Prentice, HG | 1 |
| Sacchi, S | 1 |
| Russell, N | 1 |
| Johnson, SA | 1 |
| Birchall, J | 1 |
| Luckie, C | 1 |
| Oscier, DG | 1 |
| Owen, RG | 1 |
| Chanan-Khan, AA | 1 |
| Cheson, BD | 1 |
| Kyrtsonis, MC | 1 |
| Kokoris, SI | 1 |
| Kontopidou, FN | 1 |
| Siakantaris, MP | 1 |
| Kittas, C | 1 |
| Pangalis, GA | 1 |
| Viniou, NA | 1 |
| Grigoraki, V | 1 |
| Galani, E | 1 |
| Economou, O | 1 |
| Alexanian, R | 1 |
| Weber, D | 1 |
| Desikan, R | 1 |
| Li, Z | 1 |
| Jagannath, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia[NCT02302469] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Phase II Study of Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia[NCT00142116] | Phase 2 | 25 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Phase II Clinical Study of Zanubrutinib Combined With Bendamustine and Rituximab (ZBR) for Time-limited Treatment of Waldenstrom Macroglobulinemia[NCT05914662] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-02-15 | Recruiting | ||
| Phase II Study of CC-5103 and Rituximab in Waldenstrom's Macroglobulinemia[NCT00142168] | Phase 2 | 16 participants (Actual) | Interventional | 2004-09-30 | Terminated (stopped due to Toxicity) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response determinations were made using modified consensus panel criteria from the Third International Workshop on WM, and response rates were determined on an evaluable basis. A complete response was defined as having resolution of all symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein by immunofixation, and resolution of any adenopathy or splenomegaly. Patients achieving a partial response and a minor response were defined as achieving a more than or equal to 50% and more than or equal to 25% reduction in serum IgM levels, respectively. Patients with stable disease were defined as having less than 25% change in serum IgM levels, in the absence of new or increasing adenopathy or splenomegaly and/or other progressive signs or symptoms of WM. Progressive disease was defined as a greater than 25% increase in serum IgM level occurred from the lowest attained response value or progression of clinically significant disease-related symptom(s). (NCT00142116)
Timeframe: 3 years
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Minor Response | Stable Disease | |
| All WM Patients | 1 | 15 | 2 | 7 |
Time to disease progression (TTP) was calculated from the start of therapy using the Kaplan-Meier method. (NCT00142116)
Timeframe: 49.1 months
| Intervention | months (Median) | |||
|---|---|---|---|---|
| TTP for all evaluable patients | TTP for responding patients | TTP for previously treated patients | TTP for previously untreated patients | |
| Thalidomide and Rituximab | 34.8 | 38.7 | 15.25 | 36.04 |
Major response rate is the number of participants who achieve at a PR or better. A PR or better will be defined as achieving a >50% reduction in serum IgM levels. (NCT00142168)
Timeframe: 34.3 months
| Intervention | participants (Number) |
|---|---|
| Lenalidomide and Rituximab | 4 |
A minor response is defined as having achieved >25% but less than 50% reduction in serum IgM levels. (NCT00142168)
Timeframe: 34.3 months
| Intervention | participants (Number) |
|---|---|
| Lenalidomide and Rituximab | 4 |
Overall response is the total number of participants who respond to therapy. Patients achieving a complete response (CR) will be defined as having achieved resolution of all symptoms, normalization of their serum IgM levels with complete disappearance of their IgM paraprotein by immunofixation, and resolution of any adenopathy or splenomegaly during any point while in this study and normal bone marrow biopsy. Patients achieving a partial response (PR) and a minor response (MR) will be defined as achieving a > 50% and > 25% reduction in serum IgM levels, respectively, during any point while in this study. Patients with stable disease (SD) will be defined as having < 25% change in serum IgM levels, in the absence of new or increasing adenopathy or splenomegaly and/or other progressive signs or symptoms of WMduring any point while in this study. (NCT00142168)
Timeframe: 34.3 months
| Intervention | participants (Number) |
|---|---|
| Lenalidomide and Rituximab | 8 |
Time to progression is measured as the length in time in months from starting therapy until progression, defined as 25% increase in serum IgM from nadir. (NCT00142168)
Timeframe: 34.3 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Rituximab | 17.1 |
21 reviews available for thalidomide and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
Successful treatment of Bing-Neel syndrome using intrathecal chemotherapy and systemic combination chemotherapy followed by BEAM auto-transplant: a case report and review of literature.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2013 |
Therapeutic effects of thalidomide in hematologic disorders: a review.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Graft vs Host Disease; Hematologic Neoplasms; Hum | 2013 |
Current and future therapeutic approach for Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Ant | 2014 |
Waldenstrom macroglobulinemia: prognosis and management.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; H | 2015 |
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoc | 2016 |
[Acquired von Willebrand syndrome in three patients and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hemorrhage; Humans; Immunoglobulins, I | 2016 |
Treatment of plasma cell dyscrasias with lenalidomide.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bor | 2008 |
Targeted therapies in Waldenström macroglobulinemia.
Topics: Animals; Antineoplastic Agents; Humans; Lenalidomide; Proteasome Inhibitors; Thalidomide; Waldenstro | 2008 |
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Muri | 2009 |
[IMiDs in hematology].
Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoi | 2011 |
Waldenström macroglobulinemia: my way.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acid | 2013 |
Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Clinical Tr | 2003 |
Potential new therapeutics for Waldenstrom's macroglobulinemia.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adjuvants, Immunologic; Clinical Trials as Topic; Cyclic Nucleo | 2003 |
Novel biologically based therapies for Waldenstrom's macroglobulinemia.
Topics: Adjuvants, Immunologic; Anti-Bacterial Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Enz | 2003 |
Amyloidosis and Waldenström's macroglobulinemia.
Topics: Amyloidosis; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Protocols; Drug Therapy, Comb | 2004 |
Treatment options in Waldenstrom's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Humans; Lymph | 2004 |
[Thalidomide: mechanisms of action and new insights in hematology].
Topics: Amyloidosis; Angiogenesis Inhibitors; Clinical Trials as Topic; Cytokines; Follow-Up Studies; Foreca | 2005 |
Guidelines on the management of Waldenström macroglobulinaemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cladribine; Drug Therapy, Combinatio | 2006 |
Lenalidomide for the treatment of B-cell malignancies.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Gene | 2008 |
Recent advances in treatment of multiple myeloma and Waldenström's macroglobulinemia.
Topics: Antineoplastic Agents; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; M | 2001 |
Waldenström's macroglobulinaemia: current therapy and future approaches.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Erythropoietin; Humans; Interferon-alpha; | 2002 |
5 trials available for thalidomide and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
Lenalidomide is safe and active in Waldenström macroglobulinemia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Administration Sc | 2015 |
Thalidomide and rituximab in Waldenstrom macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Ant | 2009 |
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Ant | 2009 |
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Ant | 2009 |
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Ant | 2009 |
Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Follow-Up Studies; Hu | 2003 |
Treatment of Waldenstrom's macroglobulinemia with thalidomide.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Dose- | 2001 |
13 other studies available for thalidomide and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Bortez | 2020 |
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tum | 2014 |
Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; D | 2015 |
Waldenstrom macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Female; Humans; Immunologic Factors; Lymphocytes; Middle Age | 2010 |
[A case of POEMS syndrome associated with Waldenström's macroglobulinemia and treated with lenalidomide].
Topics: Humans; Lenalidomide; Male; Middle Aged; POEMS Syndrome; Thalidomide; Waldenstrom Macroglobulinemia | 2012 |
Splenic re-irradiation for waldenstrőm's macroglobulinemia.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Disease Prog | 2012 |
Tumoral Bing-Neel Syndrome presenting as a cerebellar mass.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplas | 2013 |
Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2003 |
BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Disease Progres | 2002 |
Future directions in haematology: beyond multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Blood Transfusion; Clinical Trials, Phase II as Topic; Cytokines; | 2005 |
Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody.
Topics: Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Disease Progression; Humans; Im | 2001 |
Thalidomide in the treatment of plasma cell malignancies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Multiple Myeloma; Thalidomide; Waldenstrom M | 2001 |